The United States pays high prices for brand-name drugs, but generics — which fill nine out of 10 prescriptions — give Americans relatively low-cost access to medicines. That dynamic could change depending on the Supreme Court’s decision in Hikma v. Amarin, a case that challenges a key tool generics use to reach the market more quickly: “skinny labeling.”
Skinny labeling allows generic manufacturers to win FDA approval to market a drug only for uses that are no longer covered by a brand-name patent, avoiding patented indications. By selling versions limited to noninfringing uses, generics can often evade costly patent fights and bring lower prices to patients and insurers sooner. Over the last decade more than two dozen generics have used this path; one study estimated skinny labeling saved Medicare nearly $15 billion from 2015 to 2021.
Hikma, a generic maker, launched a copy of Amarin’s Vascepa — a purified fish-oil drug — with a skinny label in 2020 after some Vascepa patents expired. Amarin sued, alleging Hikma encouraged doctors to prescribe the generic for a still-patented use as well as the unpatented indication. Amarin pointed to marketing language and other conduct it says facilitated off-label prescribing for the patented group. A federal court sided with Amarin, but Hikma persuaded the Supreme Court to review the case.
Supporters of Hikma, including more than 70 legal scholars and the U.S. solicitor general, argue that routine marketing and neutral descriptions of a product should not expose generics to massive patent liability. They say the skinny-label pathway cannot function as Congress intended if ordinary labeling and marketing practices invite litigation. Hikma’s backers contend that constraining skinny labeling would make it too risky or expensive for generics to enter the market at the earliest opportunity.
If the Court rules for Amarin, experts warn, generic firms may shy away from skinny labels to avoid lawsuits, choosing slower, safer routes such as waiting for all patents to expire or launching designs that raise their own legal exposure. That delay could extend brand monopolies and keep prices high for longer. For example, skinny labeling allowed generic competition for Crestor to begin six years earlier than it otherwise might have, saving patients and insurers billions in just the first year of competition.
Other commentators urge caution about dire predictions. Some law professors note that skinny labeling remains an attractive and profitable strategy; even if litigation risk rises, manufacturers may accept lawsuits as a cost of bringing products to market quickly. And if the Court sides with Hikma, the immediate effect on prices would likely be negligible; generics would continue using skinny labels. Amarin warns, however, that broadly shielding skinny labeling from liability could undermine incentives for brand companies to invest in discovering new, patented uses of existing drugs.
Observers point to signs favoring Hikma: the solicitor general’s support, the Supreme Court’s tendency to reverse lower courts in many cases, and recent rulings that set a high bar for inducement or encouragement of patent infringement. Still, outcomes could vary from a broad ruling that significantly protects skinny labeling to a narrow opinion that preserves the status quo.
At stake is more than a single fish-oil drug. The Court’s decision could shape the legal and commercial environment for generic competition and, by extension, how quickly patients and payers gain access to lower-cost medicines.